M. H. Monster-Simons

Evaluation of Information in Summaries of Product Characteristics (SmPCs) on the Use of a Medicine in Patients With Hepatic Impairment

K. Taxis, P. Mol, H. Metselaar, 2019, Front. Pharmacol..

Safe use of proton pump inhibitors in patients with cirrhosis

K. Taxis, J. Drenth, H. Metselaar, 2018, British journal of clinical pharmacology.

Reported adverse drug reactions and their determinants in Dutch children outside the hospital

H. Tobi, L. de Jong-van den Berg, E. V. van Puijenbroek, 2004, Pharmacoepidemiology and drug safety.

A Review of the Dose Justification of Phase 3 Trials to Regulatory Authorities for Drugs Intended for the Treatment of Type 2 Diabetes in Europe

P. Mol, H. Heerspink, J. Stevens, 2021, Frontiers in Pharmacology.

Evidence-Based Recommendations to Improve the Safe Use of Drugs in Patients with Liver Cirrhosis

K. Taxis, J. Drenth, H. Metselaar, 2018, Drug Safety.

Evaluating the safety and dosing of drugs in patients with liver cirrhosis by literature review and expert opinion

K. Taxis, J. Drenth, H. Metselaar, 2016, BMJ Open.

Recommendations for the safe use of direct oral anticoagulants in patients with cirrhosis based on a systematic review of pharmacokinetic, pharmacodynamic and safety data.

H. Metselaar, T. Lisman, M. Mulder, 2024, European journal of clinical pharmacology.